Acura Pharmaceuticals (ACUR) and King Pharmaceuticals (KG) Provide Update on Acurox NDA
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) announced that they met with the FDA on September 2, 2009 to discuss the FDA's June 30, 2009 Complete Response Letter regarding the New Drug Application for Acurox (oxycodone HCl and niacin) Tablets CII (NDA). The FDA and the Companies agreed to take the NDA to an FDA Advisory Committee to consider the evidence to support the potential opioid abuse deterrent effects of Acurox(R) Tablets. The FDA indicated that no new clinical trials are required at this time. The FDA has not yet set a meeting date for the Advisory Committee's review of the NDA. The Companies do not expect the meeting to be convened before the end of this year.
You May Also Be Interested In
- Medicis (MRX) Gets Verbal Notice of Allowance for ZYCLARA Patent on Actinic Keratosis
- Amgen (AMGN) Says AMG 103 Achieves High-Rate of CR in B-Precursor ALL Following Phase 2 Data
- Inovio (INO) Reports Encouraging Data for SynCon Vaccine in Generating HAI Titers
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
